The company said overall survival findings from DENALI Part 1b will be delivered in a rapid oral presentation, while its Phase 3 ASPENOVA trial in Cyclin E1-positive platinum-resistant ovarian cancer will be featured in a trial-in-progress poster.
verifying reliability
No specialized terms available for this topic.